Aims: Transcatheter mitral valve implantation (TMVI) is a novel approach that may enable a less invasive effective reduction of mitral regurgitation (MR). A limitation of the MitraClip is that definitive implantation of a clip precludes future therapy with TMVI. The purpose of this paper is to describe contemporary treatment considerations in patients with mitral valve regurgitation.
Introduction
Mitral regurgitation (MR) is the most common valvular disease 1 . The prevalence of severe MR increases in elderly patients and increased longevity is projected to expand the disease burden further 2 . The optimal treatment for patients with severe symptomatic MR is either surgical valve replacement/repair or medical treatment 3, 4 . However, many patients with MR are at high risk for conventional surgery, while medical treatment is commonly ineffective [5] [6] [7] . Recently, less invasive strategies for MR reduction have been developed [8] [9] [10] [11] [12] [13] [14] . MitraClip (Abbott Vascular, Santa Clara, CA, USA) implantation is currently the most commonly utilised transcatheter therapy for severe MR. Clinical trials show that, although MitraClip implantation is relatively safe, an effective and durable outcome is frequently not achieved [15] [16] [17] [18] . Transcatheter mitral valve implantation (TMVI) is a novel approach that may, theoretically, enable a more effective reduction in MR severity [19] [20] [21] [22] . A significant concern is that a transcatheter valve cannot be implanted after a MitraClip has been deployed and released.
Case description
A 39-year-old male with dilated cardiomyopathy, resulting in severe left ventricular dysfunction, and severe functional MR had decompensated heart failure. . The patient was declined for conventional surgery because of his comorbidities. The suitability of the mitral annular anatomy for TMVI was assessed by pre-procedural CT 22, 23 . Mitral annular dimensions as well as landing zone characteristics were assessed to ensure annular dimensions within the range of the anticipated valve size as well as non-interference with anchoring mechanisms (Figure 1) . The risk of LVOT obstruction was excluded using device simulation with the CT data set, as recently described 23 ( Figure 1) . The patient had a projected mitral valve area of 1,003 mm² with a septal to lateral distance of 31 mm and an intercommissural distance of 38 mm. There was no annular calcium and a sufficient posterior shelf was noted. All these parameters seemed compatible with TMVI; however, the patient was referred for MitraClip implantation as a first-line treatment of high-risk MR patients who seem to be good candidates for the MitraClip. MitraClip implantation was attempted in August 2014. Clip capturing of both anterior and posterior leaflets did not reduce MR (Figure 2, Moving image 1 ). There was a consensus that additional clips would probably not be effective as the gap between the leaflets in this extremely dilated left ventricle was very wide. A decision was made to abort MitraClip implantation, ungrasp the leaflets, remove the device and pursue a transcatheter valve option as the patient was already considered to be a good candidate for TMVI.
Three weeks after the MitraClip attempt, in September 2014, TMVI was performed under general anaesthesia with endotracheal intubation in a hybrid operating room. The TMVI procedure was approved on compassionate grounds by Health Canada and informed consent was obtained. The Tiara™ system (Neovasc Inc., Richmond, BC, Canada) is a catheter-based self-expanding trileaflet bovine pericardial tissue mitral bioprosthesis, designed to fit an asymmetric D-shaped mitral annulus [24] [25] [26] [27] . A hydrophilic wire was inserted through the right jugular vein and into the coronary sinus to guide as an anatomical landmark for device positioning with fluoroscopy ( Figure 3A) . A mini anterior thoracotomy was performed to access the left ventricular apex. The delivery system was inserted into the left ventricle and across the mitral valve into the mid left atrium (Moving image 2). This action was followed by release of the atrial portion ( Figure 3B, Figure 3C 
. Post TMVI echocardiographic examination showing only trivial mitral valve regurgitation. A) Short axis. B) Long axis.
gradient across the outflow tract. TEE revealed secure seating of the prosthesis with normal valvular function, trivial paravalvular leakage, and a transvalvular gradient of 3 mmHg (Figure 4 , Moving image 5, Moving image 6). The patient was haemodynamically stable throughout the procedure. There were no apical access issues, and blood transfusion was not required. He was extubated in the operating room and transferred in a stable condition to the surgical intensive care unit. An increase in systemic pressure and a reduction of pulmonary pressure were evident immediately post implantation. The calculated cardiac index had increased from 1.0 L/min/m 2 at baseline to 2.7 L/min/ m 2 following TMVI. The patient was transferred to the ward on the second postoperative day for further convalescence and rehabilitation. He had a rapid recovery, and was discharged four days post implant. At two-month follow up, the patient described symptomatic improvement. Echocardiography documented the absence of mitral regurgitation with no change in LV function.
Discussion SAFETY VS. EFFICACY OF MITRACLIP IMPLANTATION
The anatomy of the mitral valve is complex 28, 29 . The valve and related structures include the annulus, valvular leaflets, chordae tendineae, and papillary muscles, and its function is closely related to the left ventricle morphology and contractility. Treatment of a single anatomic component may be ineffective. The MitraClip is the most widely utilised transcatheter device in patients with MR 15 . Repositioning before clip release is feasible, and multiple clips can be implanted if necessary. Although MitraClip implantation may be a safe and effective alternative to surgery in carefully selected high-risk patients with severe MR, its long-term durability in the absence of concomitant mitral annuloplasty is controversial 30 .
The MitraClip device was studied in the EVEREST II randomised trial, and in numerous registries, comparing it with conventional surgery [16] [17] [18] [31] [32] [33] [34] . MitraClip implantation is a relatively safe procedure. A recent analysis of 628 MitraClip implantations showed infrequent cardiac tamponade (1.1%) and stroke (0.2%). In addition, vascular damage and profuse bleeding requiring multiple transfusions were rare (1.1% and 0.7%, respectively) 18 . However, the efficacy of MR reduction post MitraClip implantation is not high. In the EVEREST II randomised trial, the primary endpoint of survival free from both surgery and significant MR at 12 months was lower with MitraClip compared to surgical valve replacement 16, 17 . e 247 EuroIntervention 2016;12:e244-e249
Transapical mitral valve implantation after MitraClip attempt
Patients having significant MR post MitraClip implantation are challenging. These patients could be treated by conventional surgery 35 . However, MitraClip implantation excludes the potentially favourable approach of TMVI, the only mechanical approach for replacing the valve in patients considered inoperable. Fortunately, as shown in the current report, operators can assess the efficacy of MitraClip implantation during the procedure and remove the device if sustained efficacy does not seem probable and the patient is anatomically suitable for TMVI.
TRANSCATHETER MITRAL VALVE IMPLANTATION
In conventional surgery, valve replacement results in a more effective and durable relief of MR than repair, especially in secondary MR 36 . It is anticipated that TMVI will result in an effective, less invasive, approach for patients with severe MR. Clinical data in these procedures are currently limited. Transcatheter technologies aiming to replace the mitral valve are more difficult to develop than those for the aortic valve. This complexity includes the non-planar D-shaped annulus, lack of a fibrous annular structure, variability of leaflet and subvalvular apparatus anatomy, and proximity to the left ventricular outflow tract, circumflex coronary artery, and coronary sinus 28, 29 . In addition, almost all of these procedures are performed utilising the transapical approach. It is already known that post apical procedure there is occasionally impairment in ventricular function 37, 38 . This further deterioration, even if only transient, is clearly not desired in patients with functional MR who have significant ventricular dysfunction. We can speculate that in the future TMVI may probably be approached using an antegrade transseptal delivery.
Conclusions
In selected centres, utilising both the MitraClip and TMVI, the approach of "MitraClip first" could be considered. In this approach, a high-risk patient with severe MR could be treated with the widely studied and relatively safe MitraClip (when anatomical criteria are met); in case of limited efficacy, the first clip will not be released and the patient will be considered for the newly developed transapical TMVI. Assessment for TMVI and patient consent should be approached at an early stage.
Impact on daily practice
The clinical approach towards high-risk patients with significant MR may change in the next few years. Robust clinical data regarding TMVI are still lacking. The most important clinical implica tion to be derived from the present report is that, since a fully implanted and released MitraClip will exclude a patient from TMVI, if a patient is considered inoperable and during MitraClip implantation there seems to be very limited efficacy, the clip should not be released and the patient should be considered for TMVI. The clinical dilemma is between adding other clips or removing the first clip and attempting TMVI. We can expect that the TMVI option will probably place increased emphasis on the importance of having evident efficacy of first clip implantation during MitraClip procedures.
